Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis (MESYNAD)
Effect of Two Methotrexate Injections in Sync With the First Adalimumab Injection to Prevent the Immunisation Anti Adalimumab During Treatment of Spondyloarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France
- Hôpital Pellegrin
-
Boulogne-Billancourt, France
- Hôpital Ambroise Paré
-
Brest, France
- Hopital La Cavale Blanche
-
Chambray-lès-Tours, France
- CHU Trousseau
-
Corbeil-Essonnes, France
- Ch Sud Francilien
-
Créteil, France
- Hopital Mondor
-
Le Kremlin-Bicêtre, France
- Kremlin Bicêtre hospital
-
Le Mans, France
- CH Le Mans
-
Lille, France
- Hôpital Saint Philibert
-
Nantes, France
- CHU Nantes
-
Orléans, France
- CHR Orléans
-
Paris, France
- Hôpital Bichat
-
Paris, France
- Hopital Saint Antoine
-
Paris, France
- Hôpital Cochin
-
Paris, France
- Hôpital La Pitié Salpêtrière
-
Pontoise, France
- CH Pontoise
-
Rouen, France
- CHU Rouen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria :
- Patients aged from 18 to 90
- Patients suffering from axial SpA, radiographic or non-radiographic according to ASAS criteria (peripheral involvement and/or Inflammatory bowel diseases could be present).
- Indication for anti TNF treatment: resistance to at least 2 NSAIDs and no contraindication to adalimumab
- No previous treatment with methotrexate in the last 3 months
- Stable dosage of steroids (less than 10mg/day of prednisone equivalent) and/or of NSAIDs for at least 10 days
- Contraception feminine or masculine
- Informed and written consent
- Social insurance
Exclusion criteria :
- Contraindication to methotrexate
- Previous treatment with adalimumab
- Steroids more than 10mg/day of prednisone equivalent
Previous treatment with:
- Etanercept in the last month
- Infliximab, golimumab, certolizumab in the last 2 months (Previous treatment hereafter these dates with anti-TNF except adalimumab or secukinumab are not a counterindication)
- Current immunosuppressive drugs except methotrexate
- Current and proven pregnancy
- Project of pregnancy in the next 3 months following inclusion
- Legal safeguards
- Inclusion in another interventional research project
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Methotrexate + Adalimumab
Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
|
Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
|
|
No Intervention: Adalimumab
Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum concentrations of ADAb anti adalimumab
Time Frame: 6 month
|
To assess if 2 subcutaneous injections of methotrexate could prevent anti adalimumab antibodies formation at month 6 in patients with spondyloarthritis
|
6 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
residual serum concentration of adalimumab
Time Frame: At 1, 3, 6 and 12 months
|
To compare trough levels of adalimumab at month 1, 3, 6 and 12 in the 2 groups.
|
At 1, 3, 6 and 12 months
|
|
serum concentrations of ADAb anti adalimumab
Time Frame: At 1, 3 and 12 months
|
To compare the percentage of immunized patients at month 1, 3 and 12 in the 2 groups
|
At 1, 3 and 12 months
|
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: At 1, 3, 6 and 12 months
|
Incidence of Treatment-Emergent Adverse Events as assessed by the number of AE and SAE related to the treatment that occur during the participation of the patient
|
At 1, 3, 6 and 12 months
|
|
Comparison of Adalimumab Therapeutic efficacity in term of therapeutic maintenance
Time Frame: At 3, 6 and 12 months
|
Assess by Number of patient who didn't switch treatment
|
At 3, 6 and 12 months
|
|
Comparison of Adalimumab Therapeutic efficacity in term of Activity disease using ASDAS (Ankylosing Spondylitis Disease Activity Score) score.
Time Frame: At 3, 6 and 12 months
|
A therapeutic efficacity will be described as a clinical pertinent change of ASDAS : Ankylosing Spondylitis Disease Activity Score (at least 1,1 point) (a higher score means a worse outcome)
|
At 3, 6 and 12 months
|
|
Comparison of Adalimumab Therapeutic efficacity in term of Activity disease using BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score.
Time Frame: At 3, 6 and 12 months
|
A therapeutic efficacity will be described as a clinical pertinent change of BASDAI : Bath Ankylosing Spondylitis Disease Activity Index (0 to 50 points - a higher score means a worse outcome)
|
At 3, 6 and 12 months
|
|
Comparison of Adalimumab Therapeutic efficacity in term of nonsteroidal anti inflammatory drugs ' reduction
Time Frame: At 3, 6 and 12 months
|
Assess by ASAS-NSAIDS score (Assessment of SpondyloArthritis international Society - nonsteroidal antiinflammatory drugs) (minimum 0. a higher score means a worse outcome)
|
At 3, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: gaetane Nocturne, APHP
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Spinal Diseases
- Bone Diseases
- Bone Diseases, Infectious
- Spondylitis
- Spondylarthritis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
Other Study ID Numbers
- APHP180571
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.